Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 04/28/26
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter SalesInvestors Business Daily • 04/28/26
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'CNBC • 04/28/26
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmedGlobeNewsWire • 04/28/26
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO PrequalificationZacks Investment Research • 04/27/26
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticariaGlobeNewsWire • 04/27/26
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infantsGlobeNewsWire • 04/24/26
Unveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 04/23/26
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMsBusiness Wire • 04/15/26
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030GlobeNewsWire • 04/09/26
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%GlobeNewsWire • 03/29/26
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapyProactive Investors • 03/27/26
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a weekCNBC • 03/27/26